



FINANCIAL SNAPSHOT

NASDAQ/TSX:	AEZS
SHARE PRICE:*	\$.35
MARKET CAP:*	~\$22.1M
SHARES OUTSTANDING:	~62.6M

*As of September 23, 2020

Investor and
Media Relations
JTC Team
833.475.8247
aezs@jtcir.com

Specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests

Where We Are Today

Macrilen™ 60 mg
(macimorelin) for oral solution

First and only approved oral drug indicated for
diagnosis of adult growth hormone deficiency (AGHD)



Partnership with global leader in growth hormone
deficiency therapeutic market in U.S. and Canada

- Receiving royalties on sales and milestone payments

Growth Opportunities

MACIMORELIN

Market in Europe
and Globally



Robust business development
effort ongoing to seek additional
commercialization partners

Childhood-Onset Growth
Hormone Deficiency (CGHD)



Leveraging AGHD approval and
compelling safety profile¹

BUILDING A PIPELINE BEYOND DIAGNOSTICS

Macimorelin as
a Therapeutic



Exploring the potential of
macimorelin as a therapeutic agent
in various indications

Pipeline
Expansion



Evaluating opportunities to
expand development pipeline

1: Macrilen [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; 2018; Macimorelin summary of product characteristics (SmPC) approved by European Commission

Macimorelin Commercial Rights

Ongoing business development
activities to secure commercialization
partner in Europe and ROW

Marketed in the United States
Under License and
Assignment Agreement



Distribution and
Commercialization Agreement in
Israel and the Palestine Authority



Owns Worldwide Rights
Outside of U.S. and Canada

Market Overview

Growth Hormone Deficiency



Children

Number of potential tests annually



27,000 - 28,800¹



~25,000¹

1: Navigant study 2009, TVG study 2017, Huron Consulting study 2018



Adult

Number of potential tests annually



28,000 - 62,000¹



14,000 - 28,000¹

Leveraging Clinical Success and Compelling Safety Profile

Expand Macimorelin Into CGHD Through Use of Pediatric Development Plan

CGHD Clinical Development Strategy

Dose Finding Study (P01)

Positive results announced April 2020



Provides Framework
for Study P02

Efficacy Study (P02): Test Efficacy and Safety

Expected commencement date

Q1
2021

- Co-Development with Novo Nordisk (NN)
- NN responsible for funding 70% of the CGHD clinical trials

Expected Value Driving Milestones

- ✓ Announced positive results from CGHD dose ranging study (AEZS-130-P01)
- ✓ Distribution and commercialization agreement with MegPharm in Israel and the Palestine Authority

Planned completion of
Study P02 in CGHD

Earliest macimorelin
CGHD approvals -
FDA and EMA

December 2019

Q2 2020

Q1 2021

Q2 2022

Q3 2022

H1 2023

- ✓ Inclusion of macimorelin in the AACE Growth Hormone Deficiency 2019 Guidelines

Planned start of CGHD safety and efficacy study (AEZS-130-P02 - multi-national, including U.S.)

Planned submission - FDA and EMA CGHD dossiers

Potential upside by pipeline activities